

**CURRICULUM VITAE  
ERIC STEPHEN WINER**

**CONTACT INFORMATION:**

Rhode Island Hospital  
Division of Hematology/Oncology  
593 Eddy Street  
Providence, RI 02903  
(401) 444-5396  
(401) 444-8918 (fax)  
[ewiner@lifespan.org](mailto:ewiner@lifespan.org)

**EDUCATION:**

**Undergraduate**

Haverford College  
Bachelors of Science, Biology 1993

**Medical School**

University of North Carolina School of Medicine Aug. 1995 – May 1999  
MD awarded

**Postgraduate Training**

**Residency**

1999- 2002      Tufts-New England Medical Center  
750 Washington Street  
Boston, MA 02111  
Internal Medicine

**Fellowship**

2002- 2005      Tufts-New England Medical Center  
750 Washington Street  
Boston, MA 02111  
Hematology/Oncology

2012-Present    Masters of Clinical and Translational research  
Brown Public Health Program

**Postgraduate Honors**

May 2004      ASCO Merit Scholar, American Society of Clinical Oncology  
2010          Healthcare Professional of the Year, Leukemia Lymphoma Society,  
2009-2013      Certificate of Recognition for Exemplary Teaching,  
Warren Alpert Medical School, Hematology course  
2012          Educator of the year, Brown Hematology/Oncology Fellowship, Warren Alpert  
Medical School

2013	Beckwith Family Award for Outstanding Teaching, Department of Medicine, Warren Alpert Medical School
2014	Dean's Excellence in Teaching Award, Warren Alpert Medical School of Brown University.

### **Professional Licenses**

MD in Rhode Island #11906

### **Board Certification**

Internal Medicine – November 2002  
 Recertification 12/2012  
 Oncology – November 2005  
 Hematology – October 2006

### **Academic Appointments**

Assistant Professor, Warren Alpert Medical School of Brown University  
 (2008-present)

### **Hospital Appointments (present)**

Attending Physician, Rhode Island Hospital (2006-present)  
 Attending Physician, Miriam Hospital (2006-Present)  
 Attending Physician, Roger Williams Medical Center (9/2005-11/2006)

### **Other Appointments**

Executive board member, Leukemia and Lymphoma Society (2009-present)  
 Steering Committee (2010-present)  
 Lymphoma Research Foundation-New England Lymphoma Rounds  
 Consultant: Television series - Crime Scene Investigators: CSI (CBS)  
 (2003-present)

### **Hospital Committees**

Residency Search Committee, Department of Medicine, Warren Alpert Medical School (2012-present)  
 Brown University Oncology Group, Data Safety Monitoring Board (2013-present)  
 Rhode Island Hospital Transfusion Committee (2014-present)

### **Membership in Societies**

2007-Present	Alliance (Cancer and Leukemia Group B)
2006- Present	Brown University Oncology Group
2002-Present	American Society of Hematology
2003-Present	American Society of Clinical Oncology
1999-Present	Massachusetts Medical Society

1999-Present    Suffolk Medical Society  
1995-Present    American Medical Association

## Publication List

### Original Publications in Peer-Reviewed Journals

1. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, **Winer E**, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. *Ann Oncology* Sept 5.
2. **Winer ES**, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, Messam CA, Kamel YM. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. *Cancer Medicine* 2014 Aug 28
3. Olszewski AJ, **Winer ES**, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. *Leuk Res* 2014; 38(8):866-873
4. Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, **Winer E**, Olszewski AJ, Al-Homsi AS, Kouttab N, Dubielecka PM. Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. *Leukemia* 2014 Apr 4.
5. Gauvini A, Reagan JL, **Winer ES**, Castillo JJ. Primary refractory Hodgkin lymphoma: Limited options and poor survival –but not always. *Am J Hematol.* 2014; 89(8):853-7
6. Castillo JJ, **Winer ES**, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. *Am J Hematol* 2014; 89(3):310-4
7. Castillo JJ, **Winer ES**, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the surveillance, Epidemiology, and End Results database. *Cancer* 2013; 119(20):3672-3679.
8. Treaba DO, Chaump M, Merriam P, Ferreira K, Souza L, **Winer ES**, Barker BE. Unusual blasts with basophilic granules in 2 cases of de novo acute myeloid leukemia with inv3 (q21q26.2) and monoomy 7 and coexpression of CD2 and cd31. *Ann Diagn Pathol* 2014;18(1):33-40.
9. Reagan JL, Fast LD, Safran H, Nevola M, **Winer ES**, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ. Cellular Immunotherapy for

refractory hematological malignancies. J Transl Med 2013 Jun19;11:150

10. Treaba DO, Khedr S, Mangray S, Jackson C, **Winer ES**. Acute myeloid leukemia evolving from JAK-2 positive primary myelofibrosis and concomitant CD5-negative mantle cell lymphoma: A case report and review of the literature. Case Report Hematol. 2012;2012:875039
11. Castillo JJ, Shum H, Lahijani M, **Winer ES**, Butera JN. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012; 53(12) 2378-82
12. Reagan J, Fast L, **Winer ES**, Safran H, Butera J, Quesenberry PJ. Mismatched allogeneic transplant. Adv Hematol. 2012;2012:784213. Adv Hematol. 2012;2012:784213.
13. **Winer ES**, Castillo JJ. CT-011, a humanized version of the murine immunomodulatory monoclonal antibody BAT, for the potential treatment of cancer. Thomsen Reuters, Key Opinions, 2012.
14. **Winer ES**, Ingham RR, Castillo JJ. PCI-32765: A novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar;21(3):355-61.
15. Castillo JJ, Furman F, **Winer ES**. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Jan;21(1):15-22 Expert Opin Investig Drugs 2012;21(1):15-22
16. Perez K, **Winer ES**. CLL: something old, something new, something borrowed..... Med Health RI 2011;94(1):15-18.
17. Reagan JL, Rosmarin A, Butera JN, Nadeem A, Schiffman FJ, Sikov WM, **Winer E**, Mega AE. Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemother Pharmacol 2011 68(4):1075-80
18. Alduaij A, Treaba DO, **Winer ES**. CD30-Positive EBV associated Diffuse Large B-cell lymphoma occurring after immunosuppressive therapy for T-cell Prolymphocytic Leukemia. Clinical Lymphoma Myeloma Leuk 2011 11(1):64-7
19. Castillo JJ, **Winer ES**, Stachurski D, Perez K, Jabbour M, Milani C, Colvin GA, Butera JN. HIV-Negative Plasmablastic Lymphoma: Not in the Mouth. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):185-9.
20. Connell NT, Cassidy HM, Berz D, **Winer ES**. Alphabet Soup: RAEB, HMA, DOE, and AFOP. Medicine and Health Rhode Island. Volume 93, Issue 12, p385-386
21. Castillo JJ, **Winer ES**, Stachurski D, Perez K, Jabbour M, Milani C, Colvin GA, Butera JN. HIV negative plasmablastic lymphoma: not in the mouth.

22. Castillo JJ, **Winer ES**, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. *Leuk Lymphoma* 2010;51(11):2047-2053
23. Castillo JJ, **Winer ES**, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. *Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma*. *Oncologist*
24. Beltran B, **Winer E**, Castillo J. *ALK-positive diffuse large B-cell lymphoma: An aggressive clinicopathological entity*. *European Journal of Clinical & Medical Oncology*, December 2009; 1(2): 5.
25. Berz D, Colvin GA, McCormack EM, **Winer ES**, Karwan P, Colvin L, Rathore R, Lum LG, Elfenbein GJ, Quesenberry PJ. Triple MEL100 Therapy in Multiple Myeloma. *Transplant Proceedings*, 2009 Nov 41(9): 3863-3867
26. Colvin GA, Berz D, Ramanathan M, **Winer ES**, Fast L, Elfenbein GJ, Quesenberry PJ. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. *Biol Blood Marrow Transplant*. 2009 Apr;15(4):421-31
27. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, **Winer E**. *ALK-Positive diffuse large B-Cell Lymphoma: report of four cases and review of the literature* *J Hematol Oncol*. 2009 Feb 27;2:11.
28. Castillo J, **Winer E**, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. *Experimental Hematology*, July 2008; 36(7): 755-768.
29. Berz D, McCormack EM, **Winer ES**, Quesenberry PJ, Colvin GA. *Cryopreservation of Hematopoietic Stem Cells*. *Am J Hematol*. 2007 Jan 31
30. Hayne C, **Winer E**, Williams T, Chaves F, Khorsand J, Mark HFL. *Acute Lymphoblastic Leukemia with a 4;11 Translocation analyzed by a combined Strategy of conventional cytogenetics, FISH, Morphology, and Cytometry and An Up-to-date Review of the Literature*. *Exp Mol Pathol*. 2006 Aug;81(1):62-71
31. **Winer ES**, Miller KM, Chan GW. *GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS*. *Oncology (Williston Park)* 2005 Apr;19(4 Suppl 2):11-4.
32. Brown DM, Matise TC, Koike G, Simon JS, **Winer ES**, et al. *An integrated genetic linkage map of the Laboratory Rat Mammalian Genome* 9 (1998) 521-530.

33. Koike G, **Winer ES**, Horiuchi M, Brown DM, Szpirer C, Dzau VJ, Jacob HJ. *Cloning, characterization, and genetic mapping of Rat Type 2 Angiotensin Receptor Gene*. Hypertension (1995) 26 (part 1) 998-1002.
34. Jacob HJ, Brown DM, Bunker RK, Daly MJ, Dzau VJ, Goodman A, Koike G....**Winer ES**, Lander ES. *A Genetic Linkage Map of the Laboratory Rat, Rattus Norvegicus*. Nature Genetics (1995) 9, 63-69.
35. Otsen M, Den Biemem M, **Winer ES**, Jacob HJ, Szpirer J, Szpirer C, Bender K, Van Zutphen BFM. *Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains*. Mammalian Genome (1995) 6(9) 595-601
36. Petterson A, **Winer ES**, Weksler-Zangen S, Lernmark A, Jacob HJ. *Predictability of heterozygosity scores and polymorphisms information content values for genetic markers*. Mammalian Genome (1995) 6(9) 512-520

#### Other peer-reviewed publications

1. **Winer ES**, Pal SE, Foss FM. *“New Frontiers in Non-Hodgkin’s Lymphoma Therapy*. In Clinical Malignant Hematology Editors Sekeres MA, Kalaycio ME, Bolwell BJ. McGraw-Hill Professional; 1 Edition, March 23, 2007
2. Songdej N, **Winer ES**. Autologous Hematopoietic Stem Cell Transplant in Non-Hodgkin’s Lymphoma. In: Non-Hodgkin’s Lymphoma: Models, Prognostic Factors and Targets.

#### Selected Abstracts

1. Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study. *Abstract 9117 2012 ASCO annual meeting*
2. Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma: Early Results of “Fol-Brite” *ASH Annual Meeting Abstracts 2012 120:3657*
3. Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort. *ASH Annual Meeting Abstracts 2012 120:2728*

4. Proton Pump Inhibitor Use and the Ability to Replete Iron Stores *ASH Annual Meeting Abstracts 2011 118:1039*
5. Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic AL Amyloidosis *ASH Annual Meeting Abstracts 2011 118:5139*
6. Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL. *ASH Annual Meeting Abstracts 2009 114:4765*
7. Non-Engraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism *ASH Annual Meeting Abstracts 2008 112:831*
8. Marrow cell genetic phenotype change induced by human lung cancer cell. *Abstract 11108 2008 ASCO annual meeting*
9. HLA-Haploidentical Cellular Immunotherapy. *ASH Annual Meeting Abstracts 2007 110:3075*
10. Dose Dense Dreifach\* Melphalan100 for Multiple Myeloma. *ASH Annual Meeting Abstracts 2006 108:5465*
11. The Haploimmunostorm Syndrome: A Distinct Clinical Entity Seen in HLA-Haploidentical Cellular Immunotherapy *ASBMT 2006, #24*
12. Priming GM-CSF and Low dose cytarabine in the treatment of high risk and elderly Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome *ASCO 2004 #6612*
13. Response to tositumomab and 131-I tositumomab (Bexxar) based on IPI score *ASH 2004 Abstract #4630*
14. Response to Bexxar (tositumomab and 131-I tositumomab) in Follicular Lymphoma base on the International Prognostic Follicular Lymphoma Index (FLIPI) *ASCO 2005 Abstract #6629*

#### **Ongoing Clinical Trials:**

1. BRUOG M299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study  
Role: Principal Investigator, Investigator Initiated Trial  
Sponsored by Millenium
2. LS-P-CASTOR: A Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVD) vs Bortezomib and

Dexamethasone (Vd) in Subjects with Relapsed or Refractory Multiple Myeloma. Sponsored by Janssen Pharmaceuticals  
Role: Principle Investigator

3. TRC117146: Testing Eltrombopag versus Placebo in Patients with Acute Myelogenous Leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine. Sponsored by GlaxoSmithKline. Role: Co-Investigator
4. TRC112765: A randomized, blinded, placebo-controlled, two-phase, sequential cohort, dose finding study to assess the safety and efficacy of an oral thrombopoietin receptor agonist, eltrombopag administered to patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Sponsored by GlaxoSmithKline. Role: Principal Investigator
5. BRUOG NHL227: Ofatumumab and bortezomib for patients with low-grade B-cell non-Hodgkin's lymphoma that relapsed 6 months beyond a rituximab-containing regimen. Sponsored by the Brown University Oncology Group. Funded by GlaxoSmithKline and Millennium Pharmaceuticals. Role: Co-Investigator
6. FOLBRITe: A multicenter, open label, phase II study of Bendamustine and Rituximab followed by 90-yttrium (Y) Ibritumomab Tiuxetan for untreated follicular lymphoma. Funded by Spectrum Pharmaceuticals. Role: Co-investigator

**Other Scholarly Activities:**

1. Ad Hoc reviewer: Cancer Medicine, 2013
2. Ad Hoc reviewer: Journal of Experimental Hematology. 2010, 2012

**Invited Presentations**

1. Speaker, Leukemia and Lymphoma Society Educational Program: *CLL and Myeloproliferative Disease*, Providence RI, 3/11/08; 5/19/09; 4/27/10
2. Speaker, 1<sup>st</sup> Annual Brown Hematologic Malignancies Symposium, Brown University: *Novel Trends in Bone Marrow Transplantation*, Providence, RI October 2008
3. Speaker, American Society of Clinical Laboratory Science – Central New England, Annual Meeting: *Acute Myeloid Leukemia and MDS* Providence RI 5/5/09



4. Speaker, Leukemia and Lymphoma Society Education Program: *Tratamiento del cancer del sangre*, Providence RI, 6/17/09; 5/25/10; 4/13/11
5. Speaker, Leukemia and Lymphoma Society Education Program: *Todo lo que necesita saber sobre canceres de la sangre* (in Spanish) Providence, RI 6/17/09; 5/25/11
6. Speaker, American Society of Clinical Laboratory Science – Central New England, Annual Meeting: *Myeloproliferative disorders* Providence, RI 5/6/10
7. Speaker, Leukemia and Lymphoma Society Education Program: *Improving treatments in Blood Cancers*, Providence RI 3/13/11
8. Speaker, 2<sup>nd</sup> Annual Brown Hematologic Malignancies Symposium, Brown University. *Recent Advances in AML*, Providence RI 3/18/11
9. Speaker, Leukemia and Lymphoma Society Education Program: *Overview of blood cancers*. Providence RI, 4/13/11
10. Speaker. Oncology Nursing Society of Rhode Island Annual Meeting. *Novel treatments in Hematologic malignancies*, Providence RI, 11/12/11
11. Speaker, Leukemia and Lymphoma Society Education Program: *Overview of Blood Cancers*, Providence RI, 4/10/12
12. Speaker, Leukemia and Lymphoma Society Education Program: *“Novel treatment in NHL”* Providence RI, 12/15/12
13. Speaker, Leukemia and Lymphoma Society Education Program: *CLL: Patients, prognosis, and promise*, Providence RI, 10/16/13
14. Speaker, Lifespan Annual Nursing Forum: *Oral Chemotherapy in Hematologic Malignancies*, Providence, RI 11/2/13

### **Hospital Teaching Roles**

- Dec 2006 – present: Attending Ward and Consult physician teach a team of Fellows, Residents, Interns, and Students for 2-3 months over the course of the Year, Rhode Island Hospital, 2006-present
- 2007-2010 Preceptor, Continuity Clinic: Hematology/Oncology Fellowship, Warren Alpert Medical School, The Miriam Hospital, Kim Perez, MD

2011-Present	Preceptor, Continuity Clinic: Hematology/Oncology Fellowship, , Warren Alpert Medical School, The Miriam Hospital, Nathan Connell, MD
2013-Present	Preceptor, Second Site Clinic: Medical Resident, Department of Medicine, Rhode Island Hospital, Pamela Egan, MD
2011-2013	Preceptor, Second Site Clinic: Medical Resident, Department of Medicine, Rhode Island Hospital, Randall Ingham, MD
2009-2011	Preceptor, Second Site Clinic: Medical Resident, Department Medicine and Pediatrics, Rhode Island Hospital, Justin Eldridge, MD
2011	Preceptor, Doctoring Course, Warren Alpert Medical School: Ruhan Nagra

## **Academic Talks**

Medical Grand Rounds, Department of Medicine, Rhode Island Hospital, “*Novel Advances in Bone Marrow Transplant*” Providence RI 2/27/07

Morbidity and Mortality Conference, Department of Medicine. “*An 18-year-old male with Abdominal Pain*” Rhode Island Hospital, Providence RI, 3/4/08

*Leukocytosis*, Morning Report, , Internal Medicine Residency Program, Rhode Island Hospital and The Miriam Hospital, 3/08

Morbidity and Mortality Conference, Department of Medicine. “*A 41-year old female with hemoptysis*” Rhode Island Hospital Providence RI, 11/4/08

*The anemias*, Noon Conference Lecture Series, Internal Medicine Residency Program, Rhode Island Hospital and The Miriam Hospital, 12/08

*The Peripheral Smear*, Noon Conference Lecture Series, Internal Medicine Residency Program, Rhode Island Hospital and The Miriam Hospital, 8/09

*Myeloproliferative Diseases*, Noon Conference Lecture Series, Internal Medicine Residency Program, Rhode Island Hospital and The Miriam Hospital, 2/10

Morbidity and Mortality Conference, Department of Medicine. “*Coagulopathy and Multiple Myeloma*” Rhode Island Hospital, Providence RI, 6/9/10

Morbidity and Mortality Conference, Department of Medicine. “*CLL and adenocarcinoma*” Rhode Island Hospital, Providence RI, 6/15/10

Morbidity and Mortality Conference Department of Medicine. “*Patient Selection and Pre-operative Management with the Novel Anticoagulants: A Review of Two Cases*” Rhode Island Hospital, Providence RI, 4/30/13

*Plasma Cell Dyscrasias*. Noon Conference Lecture Series, Internal Medicine Residency Program, Rhode Island Hospital, 5/13

Morbidity and Mortality Conference, Department of Medicine. “*Churg-strauss disease*” The Miriam Hospital, Providence RI, 9/25/13

Oncology Grand Rounds, Division of Hematology/Oncology, “*AML – 40 years, any progress?*” Rhode Island Hospital, Providence RI, 2/27/14

Oncology Grand Rounds, Division of Hematology/Oncology, “*AML – have things changed?*” Lahey Clinic, Burlington MA, 6/26/14

## **Brown University Courses:**

Lecture: “*The Acute Leukemias and Myelodysplastic syndrome*” Hematology Course, 2<sup>nd</sup> year medical students, Warren Alpert Medical School, Providence RI. 1/08, 1/09, 1/10, 1/11, 1/12, 1/13,1/14

Lecture: *“Bone Marrow Transplantation”* Hematology Course, 2<sup>nd</sup> year medical students, Warren Alpert Medical School, Providence RI 1/10, 1/11, 1/12, 1/13, 1/14

Small Group leader, Hematology course, 2<sup>nd</sup> year medical students, Warren Alpert Medical School, Providence RI 1/08, 1/09, 1/10, 1/11, 1/12, 1/13, 1/14

Lecture: *Introduction to Chemotherapy*, Brown Undergraduate course, Bearing Witness to Cancer 2/8/08

Lecture: *Dealing with Cancer*, Brown Undergraduate Course, Bearing Witness to Cancer 4/9/08

Lecture: *“Caring for the Cancer patient”* Brown Undergraduate Course, Bearing Witness to Cancer 9/16/09, 10/1/10

Lecture: *“Treatment of Cancers”* Brown Medical School Cancer Action and Reflection Elective 12/5/08

Lecture: *“Caring for the cancer patient”* Brown Medical School, Cancer Action and Reflection Elective, 9/15/10

Lecture, *“Cuidado por los pacientes que hablan español (Lecture given in Spanish)”* Brown Medical School, Cancer Action and Reflection Elective 9/26/2013